Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.

Data

Health Data

Aitia

Colin Hill

Rui Wang

Robert Miller

srujan c

Michelle Brauer

Apoorva Karkhanis

Yongan Zhao

Igor Nemer

Dan Kamalic

shahid yatoo

So-Youn Shin

McLaren Gould

Ken Levine

Joe Donahue

Jeanne Latourelle

Jan Berger

QIAN DU

Charles Homan

Bruce Church

Engineering Team

Leadership Team

Business Development

Business Operations

Teams at Aitia

Engineering Team

Leadership Team

Business Development

Business Operations